Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of etelcalcetide in pediatric secondary hyperparathyroidism on hemodialysis
2017-002411-34Phase 3
- Sponsor
- Amgen
- Start
- Jan 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of etelcalcetide in secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD), sponsored by Amgen. Primary endpoint: Achievement of at least a 30% reduction from baseline in mean iPTH during the efficacy assessment phase.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2017-002411-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002411-34.